论文信息 - Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study - 字舞流文

Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study

G. Argenziano | G. Fabbrocini | M. Napolitano | C. Patruno | K. Peris | C. Foti | G. Dal Bello | G. Girolomoni | S. Ferrucci | M. Romanelli | G. Calabrese | A. Offidani | S. Ribero | E. Nettis | L. Macchia | G. Longo | F. Rongioletti | M. Corazza | M. Talamonti | M. Galluzzo | M. Ortoncelli | G. Amoruso | A. Borghi | L. Stingeni | P. Romita | T. Bianchelli | V. Piras | N. Gori | K. Hansel | M. Iannone | L. Angileri | T. Grieco | C. Chello | E. Provenzano | M. Ferrillo | S. Dastoli | M. D. Veneri | L T A G C G S M M N K L V E S M P Angileri Bianchelli Borghi Calabrese Chello Dal Be

[1] G. Argenziano,et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real‐life study , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2] G. Argenziano,et al. Long‐term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients , 2020, The British journal of dermatology.

[3] I. Zalaudek,et al. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis , 2020, The Journal of dermatological treatment.

[4] G. Fabbrocini,et al. Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study , 2020, Clinical and experimental dermatology.

[5] A. Drucker,et al. Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate-to-severe atopic dermatitis in clinical practice: A retrospective cohort study. , 2020, Journal of the American Academy of Dermatology.

[6] John D. Davis,et al. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis , 2019, JAMA dermatology.

[7] J. Sastre,et al. Treatment of moderate‐to‐severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series , 2019, The British journal of dermatology.

[8] I. Zalaudek,et al. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis , 2019, The Journal of dermatological treatment.

[9] J. Pereyra-Rodríguez,et al. Fifty‐two week follow‐up safety and effectiveness results of dupilumab treatment of moderate‐to‐severe atopic dermatitis from a retrospective, multicentric series , 2019, Dermatologic therapy.

[10] G. Yancopoulos,et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial , 2017, The Lancet.